Panbela Therapeutics (PBLA) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 11, 2020
Document Information [Line Items]
Entity Registrant Name	Sun BioPharma, Inc.
Entity Central Index Key	0001029125
Trading Symbol	snbp
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		9,649,427
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 10,870	$ 2,449
Prepaid expenses and other current assets	335	283
Income tax receivable	228	361
Total current assets	11,433	3,093
Other noncurrent assets	52	51
Total assets	11,485	3,144
Current liabilities:
Accounts payable	422	597
Accrued expenses	632	304
Term debt	37	116
Payroll protection plan loan	103
Unsecured promissory note payable	742	742
Total current liabilities	1,936	1,759
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2020 and December 31 2019	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 9,649,427 and 6,631,308 shares issued and outstanding as of September 30, 2020 and December 31, 2019 respectively	10	7
Additional paid-in capital	54,544	42,331
Accumulated deficit	(45,146)	(41,258)
Accumulated comprehensive income	141	305
Total stockholders' equity	9,549	1,385
Total liabilities and stockholders' equity	$ 11,485	$ 3,144

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	9,649,427	6,631,308
Common stock, shares outstanding (in shares)	9,649,427	6,631,308

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
General and administrative	$ 1,223	$ 622	$ 2,348	$ 1,505
Research and development	773	720	1,805	1,578
Operating loss	(1,996)	(1,342)	(4,153)	(3,083)
Other (expense) income:
Interest expense	(3)	(3)	(12)	(2,187)
Other income (expense)	239	(219)	55	(287)
Total other income (expense)	236	(222)	43	(2,474)
Loss before income tax benefit	(1,760)	(1,564)	(4,110)	(5,557)
Income tax benefit	89	190	222	331
Net loss	(1,671)	(1,374)	(3,888)	(5,226)
Foreign currency translation adjustment	(246)	202	(164)	219
Comprehensive loss	$ (1,917)	$ (1,172)	$ (4,052)	$ (5,007)
Basic and diluted net loss per share (in dollars per share)	$ (0.21)	$ (0.23)	$ (0.55)	$ (0.97)
Weighted average shares outstanding - basic and diluted (in shares)	7,888,609	6,009,904	7,085,326	5,385,986

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	$ 35,038	$ (35,058)	$ 283	$ 268
Warrants issued		419			419
Stock-based compensation		10			10
Net loss			(1,581)		(1,581)
Foreign currency translation adjustment				(32)	(32)
Beneficial conversion feature on convertible notes payable		353			353
Common stock converted into convertible notes payable (in shares)	(7)
Common stock converted into convertible notes payable		(25)			(25)
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	35,038	(35,058)	283	268
Net loss					(5,226)
Foreign currency translation adjustment					219
Cashless exercise of warrants
Common stock converted into convertible notes payable					(25)
Balances (in shares) at Sep. 30, 2019	6,624
Balances at Sep. 30, 2019	$ 7	42,164	(40,284)	502	2,389
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Stock-based compensation		412			412
Net loss			(2,271)		(2,271)
Foreign currency translation adjustment				49	49
Conversion of convertible notes payable and accrued interest (in shares)	652
Conversion of convertible notes payable and accrued interest	$ 1	2,280			2,281
Balances (in shares) at Jun. 30, 2019	5,722
Balances at Jun. 30, 2019	$ 6	38,487	(38,910)	300	(117)
Stock-based compensation		536			536
Net loss			(1,374)		(1,374)
Foreign currency translation adjustment				202	202
Sale of common stock and warrants (in shares)	902
Sale of common stock and warrants	$ 1	3,141			3,142
Balances (in shares) at Sep. 30, 2019	6,624
Balances at Sep. 30, 2019	$ 7	42,164	(40,284)	502	2,389
Balances (in shares) at Dec. 31, 2019	6,631
Balances at Dec. 31, 2019	$ 7	42,331	(41,258)	305	1,385
Warrants issued		228			228
Stock-based compensation		112			112
Net loss			(1,798)		(1,798)
Foreign currency translation adjustment				797	797
Balances (in shares) at Mar. 31, 2020	6,631
Balances at Mar. 31, 2020	$ 7	42,671	(43,056)	1,102	724
Balances (in shares) at Dec. 31, 2019	6,631
Balances at Dec. 31, 2019	$ 7	42,331	(41,258)	305	1,385
Net loss					(3,888)
Foreign currency translation adjustment					(164)
Cashless exercise of warrants					8
Common stock converted into convertible notes payable
Balances (in shares) at Sep. 30, 2020	9,649
Balances at Sep. 30, 2020	$ 10	54,544	(45,146)	141	9,549
Balances (in shares) at Mar. 31, 2020	6,631
Balances at Mar. 31, 2020	$ 7	42,671	(43,056)	1,102	724
Stock-based compensation		264			264
Net loss			(419)		(419)
Foreign currency translation adjustment				(715)	(715)
Sale of common stock and warrants (in shares)	437
Sale of common stock and warrants		1,746			1,746
Balances (in shares) at Jun. 30, 2020	7,068
Balances at Jun. 30, 2020	$ 7	44,681	(43,475)	387	1,600
Stock-based compensation		593			593
Net loss			(1,671)		(1,671)
Foreign currency translation adjustment				(246)	(246)
Sale of common stock and warrants (in shares)	2,545
Sale of common stock and warrants	$ 3	9,218			9,221
Exercise of warrants for cash (in shares)	28
Exercise of warrants for cash		52			52
Exercise of warrants, cashless (in shares)	8
Cashless exercise of warrants
Balances (in shares) at Sep. 30, 2020	9,649
Balances at Sep. 30, 2020	$ 10	$ 54,544	$ (45,146)	$ 141	$ 9,549

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		117 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (1,671,000)	$ (1,798,000)	$ (1,374,000)	$ (1,581,000)	$ (3,888,000)	$ (5,226,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation					969,000	958,000
Amortization of debt discount						2,061,000
Amortization of debt issuance costs						12,000
Non-cash interest expense						102,000
Changes in operating assets and liabilities:
Income tax receivable					133,000	44,000
Prepaid expenses and other current assets					64,000	(12,000)
Accounts payable					(347,000)	179,000
Accrued liabilities					328,000	15,000
Net cash used in operating activities					(2,741,000)	(1,867,000)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants net of offering costs of $2					1,746,000	3,142,000	$ (45,100,000)
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $1,165					9,335,000
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7						810,000
Proceeds from exercise of warrants					52,000
Proceeds from payroll protection loan					103,000
Repayment of demand note						(25,000)
Repayments of term debt					(81,000)	(82,000)
Net cash provided by financing activities					11,155,000	3,845,000
Effect of exchange rate changes on cash					7,000	(6,000)
Net change in cash					8,421,000	1,972,000
Cash at beginning of period		$ 2,449,000		1,405,000	2,449,000	1,405,000
Cash at end of period	10,870,000		$ 3,377,000		10,870,000	3,377,000	$ 10,870,000
Supplemental disclosure of cash flow information:
Cash paid during period for interest					5,000	11,000
Supplemental disclosure of non-cash transactions:
Warrants issued for future services					228,000
Warrants issued to underwriter					353,000
Cashless exercise of warrants					8,000
Amortization of warrants as offering costs					114,000
Beneficial conversion feature on convertible notes						353,000
Warrants issued with convertible notes						419,000
Common stock converted into convertible notes payable				$ 25,000		25,000
Conversion of convertible notes payable and accrued interest into common stock						2,281,000
Issuance of unsecured promissory note in exchange of vendor accounts payable						$ 742,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Proceeds from the sale of convertible promissory notes, offering costs		$ 7
Private Placement [Member]
Proceeds from issuance of common stock and warrants, issuance costs	$ 2	$ 2
Underwritten Public Offering [Member]
Proceeds from issuance of common stock and warrants, issuance costs	$ 1,165

Note 1 - Business

Note 1 - Business	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Sun BioPharma, Inc. and its wholly-owned subsidiary, Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”), exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP- 101,

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	2. The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $45.1 2011. nine September 30, 2020, $3.9 $2.7 101, September 30, 2020, $10.9 $9.5 $9.5 September 1, 2020, $9.3 $742,000 fourth The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed not 2019 March 24, 2020. 101 101 4 In March 2020, 19” 19, 19 19 19 April 3, 2020, May 20, 2020, not May 2020.

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2019 not 10 may not

Note 4 - Liquidity and Business

Note 4 - Liquidity and Business Plan	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	4. Business Plan On September 1, 2020, 2,545,454 $9.3 June 30, 2020, $1.7 first 2022. Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP- 101 101 not not There can be no

Note 5 - Summary of Significant

Note 5 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	5. Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Stock In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management's judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not Foreign currency translation adjustments The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders' equity (deficit). During the nine September 30, 2020 2019, Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company's potential dilutive shares, which include outstanding common stock options and warrants, have not The following table sets forth the potential shares of common stock that were not September 30, 2020 2019 Employee and non-employee stock options 2,170,459 1,711,511 Common stock issuable under common stock purchase warrants 6,571,468 3,417,099 8,741,927 5,128,610

Note 6 - Indebtedness

Note 6 - Indebtedness	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Indebtedness Term debt The terms of our unsecured loan (the “Term Debt”) payable to the Institute for Commercialization of Public Research, Inc. (the “Institute”) which was amended in December 2019 December 31, 2019 December 31, 2020, September 30, 2020. 2019 $10,000. September 30, 2020 $39,000. PPP l oan On May 1, 2020, $103,000 1.0% November 1, 2020. twenty-four no May 1, 2022 may November 2020. may no not November 2020, not December 31, 2020. Other indebtedness On May 17, 2019, $742,000 not September 1, 2020 October 6, 2020,

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7 . S tock holders' Equity Public o ffering of common stock and warrants On September 1, 2020, 2,545,454 five $4.54. $10.5 $9.3 1 No. 333 239661 August 28, 2020. 4, Underwriter common stock On September 1, 2020, five 127,273 $4.538. $353,000, Exercise of Warrants to purchase common stock On September 1, 2020, 35,665 $1.875 27,500 $52,000 15,000 8,165 Private p lacement s of c ommon s tock and w arrants During the nine September 30,2020, 437,000 five $6.00. 4, Warrants to purchase common stock issued for future services On February 21, 2020, five 75,000 $6.49 $228,000 September 1, 2020, one Shares of common stock reserved for future issuance were as follows as of September 30 , 20 20 : Stock options outstanding 2,170,459 Shares available for grant under equity incentive plan 893,901 Common shares issuable under outstanding common stock purchase warrants 6,571,468 9,635,828

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	8 . S tock -based Compensation 2016 The Sun BioPharma, Inc. 2016 April 9, 2020 ( “2016 2016 2016 not 2016 ten 2016 2,800,000 September 30, 2020, 1,906,099 2016 893,901 2011 Our Board of Directors ceased making awards under the Sun BioPharma, Inc. 2011 “2011 2016 2011 2011 ten zero two September 30, 2020, 264,360 2011 Stock -based Compensation Expense General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through September 30, 2020 $1.7 September 30, 2020. Stock-based compensation expense for each of the periods presented is as follows (in thousands): Nine Months Ended September 30, 2020 2019 General and administrative $ 860 $ 573 Research and development 109 385 $ 969 $ 958 Details of options granted, exercised, cancelled or forfeited during the nine September 30, 2020 Shares Available for Grant Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2020 19,549 1,744,811 $ 6.53 $ 1,047,197 Additional shares available to grant 1,300,000 - - Granted (425,648 ) 425,648 7.48 Exercised - - - Cancelled - - - Forfeitures - - - Balance at September 30, 2020 893,901 2,170,459 $ 6.71 $ 96,122 Information about stock options outstanding, vested and expected to vest as of September 30, 2020, Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 26,360 2.25 $ 1.03 26,360 2.25 $2.275 - $2.50 38,000 3.37 $ 2.46 38,000 3.37 $2.95 - $3.70 774,100 7.57 $ 3.04 605,950 7.26 $4.50 - $8.10 751,900 7.94 $ 6.24 563,500 7.39 $9.99 - $10.10 266,048 9.18 $ 9.99 107,012 8.28 $15.10 314,051 5.65 $ 15.10 310,551 5.70 Totals 2,170,459 7.48 $ 6.36 1,651,373 7.07 Key assumptions The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the nine September 30, 2020: 2020 Common stock fair value $4.82 - $9.99 Risk-free interest rate 0.29% - 0.39% Expected dividend yield 0 Expected Option life (years) 5.00 - 5.75 Expected stock price volatility 90%

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Share-based Payment Arrangement [Policy Text Block]	Stock In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management's judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation adjustments The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders' equity (deficit). During the nine September 30, 2020 2019,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company's potential dilutive shares, which include outstanding common stock options and warrants, have not The following table sets forth the potential shares of common stock that were not September 30, 2020 2019 Employee and non-employee stock options 2,170,459 1,711,511 Common stock issuable under common stock purchase warrants 6,571,468 3,417,099 8,741,927 5,128,610

Note 5 - Summary of Significa_2

Note 5 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2020 2019 Employee and non-employee stock options 2,170,459 1,711,511 Common stock issuable under common stock purchase warrants 6,571,468 3,417,099 8,741,927 5,128,610

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	Stock options outstanding 2,170,459 Shares available for grant under equity incentive plan 893,901 Common shares issuable under outstanding common stock purchase warrants 6,571,468 9,635,828

Note 8 - Stock-based Compensa_2

Note 8 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Nine Months Ended September 30, 2020 2019 General and administrative $ 860 $ 573 Research and development 109 385 $ 969 $ 958
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Shares Available for Grant Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2020 19,549 1,744,811 $ 6.53 $ 1,047,197 Additional shares available to grant 1,300,000 - - Granted (425,648 ) 425,648 7.48 Exercised - - - Cancelled - - - Forfeitures - - - Balance at September 30, 2020 893,901 2,170,459 $ 6.71 $ 96,122
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 26,360 2.25 $ 1.03 26,360 2.25 $2.275 - $2.50 38,000 3.37 $ 2.46 38,000 3.37 $2.95 - $3.70 774,100 7.57 $ 3.04 605,950 7.26 $4.50 - $8.10 751,900 7.94 $ 6.24 563,500 7.39 $9.99 - $10.10 266,048 9.18 $ 9.99 107,012 8.28 $15.10 314,051 5.65 $ 15.10 310,551 5.70 Totals 2,170,459 7.48 $ 6.36 1,651,373 7.07
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 Common stock fair value $4.82 - $9.99 Risk-free interest rate 0.29% - 0.39% Expected dividend yield 0 Expected Option life (years) 5.00 - 5.75 Expected stock price volatility 90%

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($)	Sep. 01, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Proceeds from Issuance of Private Placement									$ 1,746,000	$ 3,142,000	$ (45,100,000)
Net Income (Loss) Attributable to Parent, Total			$ (1,671,000)	$ (419,000)	$ (1,798,000)	$ (1,374,000)	$ (2,271,000)	$ (1,581,000)	(3,888,000)	(5,226,000)
Net Cash Provided by (Used in) Operating Activities, Total									(2,741,000)	(1,867,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance			10,870,000						10,870,000		10,870,000	$ 2,449,000
Working Capital			9,500,000						9,500,000		9,500,000
Stockholders' Equity Attributable to Parent, Ending Balance			$ 9,549,000	$ 1,600,000	$ 724,000	$ 2,389,000	$ (117,000)	$ (588,000)	9,549,000	2,389,000	$ 9,549,000	$ 1,385,000	$ 268,000
Proceeds from Issuance of Common Stock, Net									$ 9,335,000
Unsecured Debt, Total	$ 742,000
Forecast [Member]
Repayments of Unsecured Debt		$ 742,000
Underwritten Public Offering [Member]
Proceeds from Issuance of Common Stock, Net	$ 9,300,000

Note 4 - Liquidity and Busine_2

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($)	Sep. 01, 2020	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Proceeds from Issuance of Common Stock, Net			$ 9,335,000
Proceeds from Issuance of Private Placement			$ 1,746,000	$ 3,142,000	$ (45,100,000)
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,545,454
Proceeds from Issuance of Common Stock, Net	$ 9,300,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			437,000
Proceeds from Issuance of Private Placement		$ 1,700,000

Note 5 - Summary of Significa_3

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Anti-dilutive securities (in shares)	8,741,927	5,128,610
Share-based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	2,170,459	1,711,511
Warrant [Member]
Anti-dilutive securities (in shares)	6,571,468	3,417,099

Note 6 - Indebtedness (Details

Note 6 - Indebtedness (Details Textual) - USD ($)	May 01, 2020	Sep. 30, 2020	May 17, 2019
Proceeds from Paycheck Protection Program Under CARES Act	$ 103,000
Term Debt [Member]
Debt Instrument, Periodic Payment, Total		$ 10,000
Short-term Debt, Total		$ 39,000
Unsecured Promissory Note [Member]
Unsecured Long-term Debt, Noncurrent			$ 742,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	Sep. 01, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Feb. 21, 2020
Proceeds from Issuance of Common Stock, Net			$ 9,335,000
Stock Issued During Period, Value, Exercise of Warrants for Cash		$ 52,000
Underwritten Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.538
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	127,273
Warrants and Rights Outstanding	$ 353,000
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)	$ 1.875
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	15,000
Warrants in Connection with the Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)		5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6	$ 6
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		437,000	437,000
Warrants Issued for Future Services [Member]
Warrants and Rights Outstanding, Term (Year)					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 6.49
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					75,000
Warrants and Rights Outstanding					$ 228,000
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,545,454
Proceeds from Issuance or Sale of Equity, Total	$ 10,500,000
Proceeds from Issuance of Common Stock, Net	$ 9,300,000
Stock Issued During Period, Shares, Warrants Exercised (in shares)	35,665
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)	27,500
Stock Issued During Period, Value, Exercise of Warrants for Cash	$ 52,000
Stock Issued During Period, Shares, Exercise of Warrants on Cashless Basis (in shares)	8,165
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			437,000

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) - shares	Sep. 30, 2020	Dec. 31, 2019
Stock options outstanding (in shares)	2,170,459
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	893,901	19,549
Common shares issuable under outstanding common stock purchase warrants (in shares)	6,571,468
Common Stock, Capital Shares Reserved for Future Issuance	9,635,828

Note 8 - Stock-based Compensa_3

Note 8 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	9,635,828
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	2,170,459	1,744,811
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	893,901	19,549
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 1.7
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	1,906,099
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	893,901
Sun BioPharma, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	264,360
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	0 years
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years

Note 8 - Stock-based Compensa_4

Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based compensation expense	$ 969	$ 958
General and Administrative Expense [Member]
Share-based compensation expense	860	573
Research and Development Expense [Member]
Share-based compensation expense	$ 109	$ 385

Note 8 - Stock-based Compensa_5

Note 8 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Balance, shares available for grant (in shares)	19,549
Balance, shares underlying options (in shares)	1,744,811
Balance, weighted average exercise price per share (in dollars per share)	$ 6.53
Aggregate intrinsic value	$ 96,122	$ 1,047,197
Additional shares available to grant (in shares)	1,300,000
Granted, shares available for grant (in shares)	(425,648)
Granted, shares underlying options (in shares)	425,648
Granted, weighted average exercise price per share (in dollars per share)	$ 7.48
Balance, shares available for grant (in shares)	893,901
Balance, shares underlying options (in shares)	2,170,459
Balance, weighted average exercise price per share (in dollars per share)	$ 6.71

Note 8 - Stock-based Compensa_6

Note 8 - Stock-based Compensation - Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Options outstanding (in shares) | shares	2,170,459
Options outstanding, weighted average remaining contractual life (Year)	7 years 175 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.36
Options excercisable (in shares) | shares	1,651,373
Options excercisable, weighted average remaining contractual life (Year)	7 years 25 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 0.875
Per share exercise price, upper limit (in dollars per share)	$ 1.10
Options outstanding (in shares) | shares	26,360
Options outstanding, weighted average remaining contractual life (Year)	2 years 91 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.03
Options excercisable (in shares) | shares	26,360
Options excercisable, weighted average remaining contractual life (Year)	2 years 91 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.275
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Options outstanding (in shares) | shares	38,000
Options outstanding, weighted average remaining contractual life (Year)	3 years 135 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.46
Options excercisable (in shares) | shares	38,000
Options excercisable, weighted average remaining contractual life (Year)	3 years 135 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Per share exercise price, upper limit (in dollars per share)	$ 3.70
Options outstanding (in shares) | shares	774,100
Options outstanding, weighted average remaining contractual life (Year)	7 years 208 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.04
Options excercisable (in shares) | shares	605,950
Options excercisable, weighted average remaining contractual life (Year)	7 years 94 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 4.50
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Options outstanding (in shares) | shares	751,900
Options outstanding, weighted average remaining contractual life (Year)	7 years 343 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.24
Options excercisable (in shares) | shares	563,500
Options excercisable, weighted average remaining contractual life (Year)	7 years 142 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 9.99
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Options outstanding (in shares) | shares	266,048
Options outstanding, weighted average remaining contractual life (Year)	9 years 65 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.99
Options excercisable (in shares) | shares	107,012
Options excercisable, weighted average remaining contractual life (Year)	8 years 102 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15.10
Options outstanding (in shares) | shares	314,051
Options outstanding, weighted average remaining contractual life (Year)	5 years 237 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.10
Options excercisable (in shares) | shares	310,551
Options excercisable, weighted average remaining contractual life (Year)	5 years 255 days

Note 8 - Stock-based Compensa_7

Note 8 - Stock-based Compensation - Stock Option Valuation Assumption (Details) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2020$ / shares
Expected dividend yield	0.00%
Expected stock price volatility	90.00%
Minimum [Member]
Common stock fair value (in dollars per share)	$ 4.82
Risk-free interest rate	0.29%
Expected Option life (years) (Year)	5 years
Maximum [Member]
Common stock fair value (in dollars per share)	$ 9.99
Risk-free interest rate	0.39%
Expected Option life (years) (Year)	5 years 273 days